ABSTRACT
Luminal A and basal subtypes are two of the major subtypes that are characterized by opposite features both clinically and at the genomic level [4]. Luminal A BCs are the most frequent (45% total occurrence). They are low-grade, differentiated tumors that express hormonal receptors and the ESR1 and GATA3 luminal differentiation genes. They are usually associated with a relatively favorable prognosis due to their response to hormonal therapy. The basal subtype represents 15% of all BCs. Basal BCs are high-grade, proliferative tumors that are hormone receptor negative and associated with poor prognosis [4]. While basal tumors are relatively chemosensitive, the effectiveness of chemotherapy remains limited.
